3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate
Authors' conclusion
3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
Study context
- Population
- Women with postmenopausal osteoporosis in FRAME and ARCH with TH DXA scans at baseline and months 12 and 24 who consented to future research
- Participants
- 187 / 190 / 183 / 185
- Comparison
- Romosozumab vs placebo followed by denosumab (FRAME); romosozumab vs alendronate followed by alendronate (ARCH)
- FRAME: Romosozumabn = 187
- FRAME: Placebon = 190reference
- ARCH: Romosozumabn = 183
- ARCH: Alendronaten = 185reference
- Primary endpoint
- Percentage changes from baseline in areal BMD (aBMD), integral volumetric BMD (vBMD), cortical thickness, cortical vBMD, cortical surface BMD (sBMD) and trabecular vBMD (3D-SHAPER from TH DXA)
- Follow-up
- Months 12 and 24
Methodological detailssubset analysis, DXA-based 3D modeling (3D-SHAPER)
- Subset analysis
- DXA-based 3D modeling (3D-SHAPER)
Primary result
As reported in the abstract
Changes in aBMD, integral vBMD, cortical thickness, cortical vBMD, cortical sBMD and trabecular vBMD · month 12
- Greater increases in all parameters with romosozumab vs placebo (FRAME) and romosozumab vs alendronate (ARCH) (P < .05 for all)
- Post hoc
Further findings
Cumulative gains in all parameters · month 24
- Greater with romosozumab-to-denosumab vs placebo-to-denosumab and romosozumab-to-alendronate vs alendronate-to-alendronate (P < .05 for all)
Original publication
3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. J Bone Miner Res. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →